KCM
BDTX icon

Kathmere Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Kathmere Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Sell
10,248
-3,565
-26% -$8.72K ﹤0.01% 676
2026
Q1 		$29.4K Sell
13,813
-18,009
-57% -$42.8K ﹤0.01% 621
2025
Q4 		$77.3K Buy
31,822
+7,539
+31% +$26.7K 0.01% 551
2025
Q3 		$92K Buy
+24,283
New +$71K 0.01% 514

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Kathmere Capital Management's BDTX Position: Q2 2026 in Review

Kathmere Capital Management reduced its Black Diamond Therapeutics (BDTX) stake by 26% in Q2 2026, selling an estimated $8.72K and leaving 10,248 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #676.

Kathmere Capital Management first reported a position in BDTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $92K in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Kathmere Capital Management held 10,248 shares of Black Diamond Therapeutics worth $19K as of Q2 2026.
  • Kathmere Capital Management sold 3,565 Black Diamond Therapeutics shares in Q2 2026, an estimated $8.72K.
  • Black Diamond Therapeutics made up ﹤0.01% of Kathmere Capital Management's portfolio in Q2 2026, its #676 holding.
  • Kathmere Capital Management first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Kathmere Capital Management's Black Diamond Therapeutics position peaked at $92K in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.